A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Launched by NOVO NORDISK A/S · Jan 30, 2023
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- • 2. The decision to initiate treatment with commercially available Sogroya (somapacitan) has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.
- • 3. Male or female, age above or equal to 18 years assigned to Sogroya (somapacitan) treatment at the time of signing informed consent.
- • 4. Diagnosis of adult growth hormone deficiency (AGHD) as per local practice.
- Exclusion Criteria:
- • 1. Previous participation in this study. Participation is defined as signed informed consent.
- • 2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- • 3. Participant with hypersensitivity to the active substance or to any of the excipients.
- • 4. Participant with active malignancy or in treatment for active pre-existing malignancy.
- • 5. Participant with acute critical illness, suffering from complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions per investigator judgement.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Dallas, Texas, United States
New York, New York, United States
Saint Louis, Missouri, United States
Phoenix, Arizona, United States
Portland, Oregon, United States
Chapel Hill, North Carolina, United States
Phoenix, Arizona, United States
Atlanta, Georgia, United States
Portland, Oregon, United States
West Palm Beach, Florida, United States
Greenville, North Carolina, United States
Aurora, Colorado, United States
Aachen, , Germany
Ljubljana, , Slovenia
Las Vegas, Nevada, United States
Los Angeles, California, United States
Aurora, Colorado, United States
Los Angeles, California, United States
München, , Germany
Atlanta, Georgia, United States
Boston, Massachusetts, United States
New York, New York, United States
Oldenburg, , Germany
Omaha, Nebraska, United States
Reno, Nevada, United States
Westminster, California, United States
Reno, Nevada, United States
Shavano Park, Texas, United States
Oldenburg, , Germany
Omaha, Nebraska, United States
Chapel Hill, North Carolina, United States
Greenville, North Carolina, United States
Westminster, California, United States
Jeddah, , Saudi Arabia
Shavano Park, Texas, United States
Riyadh, , Saudi Arabia
Frankfurt Am Main, , Germany
Jeddah, , Saudi Arabia
Riyadh, , Saudi Arabia
Seattle, Washington, United States
Oldenburg, , Germany
Seattle, Washington, United States
München, , Germany
Riyadh, , Saudi Arabia
München, , Germany
Ljubljana, , Slovenia
Las Vegas, Nevada, United States
Palo Alto, California, United States
Jeddah, , Saudi Arabia
Frankfurt Am Main, , Germany
Los Angeles, California, United States
Seattle, Washington, United States
Aachen, , Germany
München, , Germany
Jeddah, , Saudi Arabia
Dallas, Texas, United States
Los Angeles, California, United States
Seattle, Washington, United States
New York, New York, United States
El Paso, Texas, United States
Seattle, Washington, United States
Okayama Shi, Okayama, , Japan
Kagoshima Shi, Kagoshima, , Japan
Kawasaki Shi, Kanagawa, , Japan
Weatherford, Texas, United States
Chikushino Shi, Fukuoka, , Japan
Kobe Shi, Hyogo, , Japan
Osaka Shi, Osaka, , Japan
Center Valley, Pennsylvania, United States
Dallas, Texas, United States
Mainz, , Germany
Chicago, Illinois, United States
Patients applied
Trial Officials
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials